About the Human Immunodeficiency Virus Session
Recent advancements in cancer research have shed light on the intricate relationship between Human Immunodeficiency Virus (HIV) and certain types of cancer. HIV, by weakening the immune system, increases susceptibility to various cancers, including Kaposi's sarcoma, non-Hodgkin lymphoma, and cervical cancer. Understanding the molecular mechanisms underlying this association has become pivotal in developing targeted therapies. Researchers are investigating how HIV proteins interact with cellular pathways involved in cancer development and progression. Additionally, they explore the impact of antiretroviral therapy on cancer risk among HIV-positive individuals. This interdisciplinary approach holds promise in not only elucidating the pathogenesis of HIV-associated cancers but also in devising more effective treatment strategies tailored to this vulnerable population.
Topics Covered in Human Immunodeficiency Virus
AIDS-Defining Cancers
Non-AIDS-Defining Cancers
Immune Dysregulation
Antiretroviral Therapy
Oncogenic Coinfections
Drug Interactions
Related Scientific Sessions at CIOC 2027
Why Attend the Human Immunodeficiency Virus Conference 2027
Earn CPD Credit
Sessions are CPD-accredited; certificates issued to every registered delegate within two weeks of the conference.
Present Your Research
Oral and poster slots for original Human Immunodeficiency Virus work, reviewed by the scientific committee.
Network Globally
Meet oncologists, cancer researchers, and clinical specialists from around the world across three days.
Publish & Get Indexed
Accepted abstracts appear in the indexed conference proceedings with a citable DOI.
Learn from Keynotes
Plenary lectures from leading voices shaping Human Immunodeficiency Virus research and practice.
Hybrid Flexibility
Attend in person in Singapore or join virtually — same programme, same certificate.
Join CIOC 2027 for the Human Immunodeficiency Virus track
Oral and poster slots for your work — in person in Singapore or online. Not presenting? Attend as a delegate to learn from the field.
Human Immunodeficiency Virus Conference 2027 — FAQs
What is the Human Immunodeficiency Virus track at CIOC 2027?
The Human Immunodeficiency Virus track is a dedicated stream within CIOC 2027 covering the latest research, clinical innovation, and best practice in Human Immunodeficiency Virus. It brings together researchers, educators, and practitioners for oral presentations, posters, and discussion.
Who should attend the Human Immunodeficiency Virus sessions?
Cancer researchers and clinicians, educators and students with an interest in Human Immunodeficiency Virus are all welcome — whether presenting or attending.
Can I present my research in the Human Immunodeficiency Virus track?
Yes. Submit an abstract for oral or poster presentation. All submissions are peer-reviewed by the scientific committee; accepted abstracts appear in the indexed proceedings.
Is virtual attendance available for Human Immunodeficiency Virus sessions?
Yes. CIOC 2027 is a hybrid conference — attend the Human Immunodeficiency Virus track in person in Singapore or join live online, with on-demand access afterward.
Join the CIOC 2027 delegation
Singapore · March 15–17, 2027· Hybrid · in-person & virtual
Attend without presenting.